Resultats de la cerca - Francesco Passamonti

Refinar resultats
  1. 1
    How I treat polycythemia vera

    How I treat polycythemia vera per Francesco Passamonti

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Clinical relevance of JAK2 (V617F) mutant allele burden

    Clinical relevance of JAK2 (V617F) mutant allele burden per Francesco Passamonti, Elisa Rumi

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  3. 3
    Update from the latest WHO classification of MPNs: a user’s manual

    Update from the latest WHO classification of MPNs: a user’s manual per Francesco Passamonti, Margherita Maffioli

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    The role of JAK2 inhibitors in MPNs 7 years after approval

    The role of JAK2 inhibitors in MPNs 7 years after approval per Francesco Passamonti, Margherita Maffioli

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Myelofibrosis

    Myelofibrosis per Francesco Passamonti, Barbara Mora

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  6. 6
    Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia

    Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia per Alessandro Squizzato, Erica Romualdi, Francesco Passamonti, Saskia Middeldorp

    Publicat 2013
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  7. 7
    Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies

    Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies per Francesco Passamonti, Margherita Maffioli, Domenica Caramazza, Mario Cazzola

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis

    Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis per Francesco Passamonti, Francisco Cervantes, Alessandro M. Vannucchi, Enrica Morra, Elisa Rumi, Mario Cazzola, Ayalew Tefferi

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Anemia in myelofibrosis: Current and emerging treatment options

    Anemia in myelofibrosis: Current and emerging treatment options per Francesco Passamonti, Claire Harrison, Ruben A. Mesa, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Srđan Verstovšek

    Publicat 2022
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  10. 10
    Transfusion‐dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is independent of IPSS or karyotype

    Transfusion‐dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is... per Ayalew Tefferi, Sergio Siragusa, Kebede Hussein, Susan M. Schwager, Curtis A. Hanson, Animesh Pardanani, Francisco Cervantes, Francesco Passamonti

    Publicat 2009
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis

    Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis per Nico Gagelmann, Francesco Passamonti, Christine Wolschke, Radwan Massoud, Christian Niederwieser, Raissa Adjallé, Barbara Mora, Francis Ayuk, Nicolaus Kröger

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  12. 12
    A Gain-of-Function Mutation of<i>JAK2</i>in Myeloproliferative Disorders

    A Gain-of-Function Mutation of<i>JAK2</i>in Myeloproliferative Disorders per Róbert Královics, Francesco Passamonti, Andreas Buser, Soon-Siong Teo, Ralph Tiedt, Jakob Passweg, André Tichelli, Mario Cazzola, Radek C. Skoda

    Publicat 2005
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS

    Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS per Chiara Elena, Francesco Passamonti, Elisa Rumi, Luca Malcovati, Luca Arcaini, Emanuela Boveri, Michele Merli, Daniela Pietra, Cristiana Pascutto, Mario Lazzarino

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients

    Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients per Elisa Rumi, Francesco Passamonti, Chiara Elena, Daniela Pietra, Luca Arcaini, C. Astori, Silvia Zibellini, Emanuela Boveri, C. Pascutto, Mario Lazzarino

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Long-term Events in Adult Patients with Clinical Stage IA-IIA Nonbulky Hodgkin's Lymphoma Treated with Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuvant Radiotherapy: A Single-Institution 15-Year Follow-up

    Long-term Events in Adult Patients with Clinical Stage IA-IIA Nonbulky Hodgkin's Lymphoma Treated with Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuv... per Ercole Brusamolino, A. Baio, Ester Orlandi, Luca Arcaini, Francesco Passamonti, Vassiliki Griva, William Casagrande, Cristiana Pascutto, P. Franchini, Mario Lazzarino

    Publicat 2006
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia

    Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia per Guido Finazzi, Alessandra Carobbio, Paola Guglielmelli, Chiara Cavalloni, Silvia Salmoiraghi, Alessandro M. Vannucchi, Mario Cazzola, Francesco Passamonti, Alessandro Rambaldi, Tiziano Barbui

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib

    Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib per Francesco Passamonti, Siddhi Korgaonkar, Rohan Parikh, Manoj Chevli, Aylin Yücel, Julien Rombi, Shalon Jones, Dieter Zissler, Keith L. Davis, Samantha Slaff

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms

    The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms per Damla Olcaydu, Elisa Rumi, Ashot S. Harutyunyan, Francesco Passamonti, Daniela Pietra, Cristiana Pascutto, Tobias Berg, Roland Jäger, E. Hammond, M. Cazzola, Róbert Královics

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2

    Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 per Róbert Královics, Soon-Siong Teo, Andreas Buser, Martin Brutsche, Ralph Tiedt, André Tichelli, Francesco Passamonti, Daniela Pietra, Mario Cazzola, Radek C. Skoda

    Publicat 2005
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Defining disease modification in myelofibrosis in the era of targeted therapy

    Defining disease modification in myelofibrosis in the era of targeted therapy per Naveen Pemmaraju, Srđan Verstovšek, Ruben A. Mesa, Vikas Gupta, Jacqueline S. Garcia, Joseph M. Scandura, Stephen T. Oh, Francesco Passamonti, Konstanze Döhner, Adam J. Mead

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:

Eines de cerca: